Nilotinib and Imatinib Utilization in Iran over 14 years

• Main Authors: Ava Mansouri (Author), Kimia Hirbod (Author), Maryam Taghizadeh-Ghehi (Author), Aarefeh Jafarzadeh Kohneloo (Author), Mohammad Solduzian (Author), Molouk Hadjibabaie (Author)
• Format: Book
• Published: Research Center for Rational Use of Drugs (RCRUD), 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML) treatment. CML healthcare costs greatly exceed of other haematological malignancies treatment mostly due to TKIs. There are several generic and brand preparations of imatinib and nilotinib, the only...